Novartis' Kisqali Prolongs Progression Free Survival Benefit In Metastatic Breast Cancer Versus Chemo

Novartis AG (NYSE:NVS) announced results from the RIGHT Choice Phase 2 trial evaluating Kisqali (ribociclib) plus endocrine therapy (ET) against combination chemotherapy (CT) in the first-line setting for pre- and perimenopausal patients with aggressive forms of hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2−) metastatic breast cancer.
Kisqali demonstrated a nearly one-year progression-free survival (PFS) benefit, supporting the superiority of Kisqali plus ET for this hard-to-treat patient population, Novartis said in a statement.
Also read: Novartis' Malaria Treatment Candidate To Move Forward With Phase 3 Development Next Year.
The study enrolled 222 patients with aggressive forms of HR+/HER2− metastatic breast cancer.
The median time to treatment failure with Kisqali plus ET was 18.6 months compared to 8.5 months with combination CT.
Patients in the Kisqali plus ET arm of the trial reported lower rates of treatment-related serious adverse events (AEs) and lower rates of discontinuation due to treatment-related AEs, compared to patients in the combination CT trial arm.
Overall, the Kisqali safety profile was consistent with previously reported data.
Price Action: NVS shares are up 1.22% at $91.85 on the last check Wednesday.

To add Benzinga News as your preferred source on Google, click here.